Advertisement

Fibrinogen Proteolysis and Coagulation System Activation during Thrombolytic Therapy

  • John Owen
  • Betty Grossman
  • Joan Sobel
  • Bohdan Kudryk
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 281)

Abstract

Thrombolytic treatment of patients with acute myocardial infarction is now well accepted as the treatment of choice in most settings (24). At this time most data has been accumulated with the use of streptokinase, and this drug has been convincingly demonstrated to reduce mortality (5). Reperfusion is achieved in 45–75% of patients, with direct intracoronary administration being slightly more effective than administration by the intravenous route (25). Some problems remain, bleeding is significant and rethrombosis continues to be an obstacle (7).

Keywords

Acute Myocardial Infarction Thrombolytic Therapy Tissue Plasminogen Activator Plasmin Action Intracoronary Streptokinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. R. Bergmann, K. A. Fox, M. M. Ter Pogossian, B. E. Sobel, and D. Collen, Clot-selective coronary thrombolysis with tissue-type plasminogen activator, Science, 220:1181–1183 (1983).PubMedCrossRefGoogle Scholar
  2. 2.
    D. Collen, E. J. Topol, A. J. Tiefenbrunn, H. K. Gold, M. L. Weisfeldt, B. E. Sobel, R. C. Leinbach, J. A. Brinker, P. A. Ludbrook, I. Yasuda, N. H. Bulkley, A. K. Robison, A. M. Jr. Hutter, W. R. Bell, J. J. Jr. Spadaro, B. A. Khaw, and E. B. Grossbard, Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial, Circulation, 70:1012–1017 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    T. Eckhardt, H. L. Nossel, A. Hurlet Jensen, K. S. LaGamma, J. Owen, and M. Auerbach, Measurement of desarginine fibrinopeptide B in human blood, J. Clin. Invest., 67:809–816 (1981).PubMedCrossRefGoogle Scholar
  4. 4.
    W. Flameng, F. Van de Werf, J. Vanhaecke, M. Verstraete, and D. Collen, Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates, J. Clin. Invest., 75:84–90 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, Lancet,397–401 (1986).Google Scholar
  6. 6.
    H. K. Gold, R. C. Leinbach, H. D. Garabedian, T. Yasuda, J. A. Johns, E. B. Grossbard, I. Palacios, and D. Collen, Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion, Circulation,73:347–352 (1986).PubMedCrossRefGoogle Scholar
  7. 7.
    H. K. Gold, R. C. Leinbach, I. F. Palacios, T. Yasuda, P. C. Block, M. J. Buckley, C. W. Akins, and W. M. Daggett, Coronary reocclusion after selective administration of streptokinase, Circulation, 68:150–154 (1983).Google Scholar
  8. 8.
    B. Kudryk, A. Rohoza, M. Ahadi, J. Chin, and M. E. Wiebe, Specificity of a monoclonal antibody for the NH2-terminal region of fibrin, Mol. Immunol., 21:89–94 (1984).PubMedCrossRefGoogle Scholar
  9. 9.
    C. Y. Liu, J. H. Sobel, J. I. Weitz, K. L. Kaplan, and H. L. Nossel, Immunologic identification of the cleavage products from the A-alpha and B-beta chains in the early stages of plasmin digestion of fibrinogen. Thrombos Haemostas, 56:100–106 (1986).Google Scholar
  10. 10.
    V. J. Marder, N. R. Shulman, and W. R. Carroll, The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage, Trans. Assoc. Am. Physicians, 80:156–167 (1967).PubMedGoogle Scholar
  11. 11.
    R. P. McDonagh, J. McDonagh, and F. Duckert, The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis. Brit. J. Haematol., 21:232–332 (1971).CrossRefGoogle Scholar
  12. 12.
    H. L. Nossel, J. Wasser, K. L. Kaplan, K. S. LaGamma, I. Yudelman, and R. E. Canfield, Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline, J. Clin. Invest., 64:1371–1378 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    J. Owen, K. D. Friedman, B. Grossman, C. Wilkins, A. D. Berke, and E. R. Powers, Quantitation of fragment X formation during thrombolytic therapy with streptokinase and with tissue plasminogen activator, J. Clin. Invest., 79:1642–1649 (1987).PubMedCrossRefGoogle Scholar
  14. 14.
    J. Owen, K. D. Friedman, B. A. Grossman, C. Wilkins, A. D. Berke, and E. R. Powers, Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin action. Blood, 72:616–620 (1988).PubMedGoogle Scholar
  15. 15.
    D. Pennica, W. E. Holmes, W. J. Kohr, R. N. Harkins, G. A. Vehar, C. A. Ward, W. F. Bennett, E. Yelverton, P. H. Seeburg, H. L. Heyneker, D. V. Goeddel, and D. Collen, Cloning and expression of human tissue-type plasminogen activator cDNA in E. coliNature, 301:214–221 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    S. V. Pizzo, M. L. Schwartz, R. L. Hill, and P. A. McKee, The effect of plasmin on the subunit structure of fibrinogen, J. Biol. Chem., 247:636–645 (1972).PubMedGoogle Scholar
  17. 17.
    P. Rentrop, H. Blanke, K. R. Karsch, W. Rutsch, M. Schartl, W. Merx, R. Dorr, D. Mathey, and K. Kuch, Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction, Am. Heart J., 102:1188–1193 (1981).PubMedCrossRefGoogle Scholar
  18. 18.
    L. L. Shen, R. P. McDonagh, J. McDonagh, and J. Hermans, Early events in the plasmin digestion of fibrinogen and fibrin: effects of plasmin on fibrin polymerization, J. Biol. Chem., 252:6184–6189 (1977).PubMedGoogle Scholar
  19. 19.
    The TIMI Study Group, The thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings, New. Eng. J. Med., 312:932–936 (1985).Google Scholar
  20. 20.
    F. Van de Werf, S. R. Bergmann, K. A. Fox, H. de Geest, C. F. Hoyng, B. E. Sobel, D. Cohen, and B. E. Sobel, Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology, Circulation, 69:605–610 (1984).PubMedCrossRefGoogle Scholar
  21. 21.
    F. Van de Werf, P. A. Ludbrook, S. R. Bergmann, A. J. Tiefenbrunn, K. A. Fox, H. de Geest, M. Verstraete, D. Collen, and B. E. Sobel, Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction, N. Engl. J. Med., 310:609–613 (1984).PubMedCrossRefGoogle Scholar
  22. 22.
    M. Verstraete, R. Bernard, M. Bory, R. W. Brower, D. Collen, D. P. de Bono, R. Erbel, W. Huhmann, R. J. Lennane, J. Lubsen, D. Mathey, J. Meyer, H. R. Michels, W. Rutsch, M. Schartl, W. Schmidt, R. Uebis, and R. von Essen, Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction, Lancet, 1:842 (1985).PubMedCrossRefGoogle Scholar
  23. 23.
    M. Verstraete, W. Bleifeld, R. W. Brower, B. Charbonnier, D. Collen, D. P. de Bono, A. J. Dunning, R. J. Lennane, J. Lubsen, D. G. Mathey, P. L. Michel, Ph. Raynaud, J. Schofer, A. Vahanian, J. Vanhaeke, G. A. van de Kley, F. Van de Werf, and R. von Essen, Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction, Lancet, 2:965 (1985).PubMedCrossRefGoogle Scholar
  24. 24.
    M. Verstrate, Intravenous administration of thrombolytic agent is the only realistic approach in evolving myocardial infarction, Eur. Heart J., 6:586 (1985).Google Scholar
  25. 25.
    S. Yusef, R. Collins, R. Peto, C. Furberg, M. J. Stampfer, S. Z. Goldhaber, and C. H. Hennekens, Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials, Eur. Heart J., 6:556 (1985).Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • John Owen
    • 1
    • 2
    • 3
  • Betty Grossman
    • 1
    • 2
    • 3
  • Joan Sobel
    • 1
    • 2
    • 3
  • Bohdan Kudryk
    • 1
    • 2
    • 3
  1. 1.The Bowman Gray School of MedicineWake Forest UniversityWinston-SalemUSA
  2. 2.The College of Physicians and SurgeonsColumbia UniversityNew YorkUSA
  3. 3.the Lindsley E. Kimball Research Institute of the New York Blood CenterNew YorkUSA

Personalised recommendations